Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug ...

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

A key rival could be Johnson & Johnson's recently-approved Invega Hafyera (paliperidone ... Since then, newer new drugs Austedo (deutetrabenazine) for Huntington's disease and migraine therapy ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire Intra-Cellular Therapies, a company whose main asset has the potential to ...

Second place was Johnson & Johnson’s schizophrenia treatment Invega Sustenna/Invega Trinza ... 10.7% net – which added $203 million to US drug spending. The biggest price increases were ...

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

Oct 21, 2024 13:33 Alembic Pharma Gets USFDA Nod for Generic Schizophrenia Drug Alembic Pharmaceuticals receives USFDA approval for its generic version of Paliperidone extended-release tablets, ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.